Anne Bruinvels joins EPEMED as executive director

Targeted with growing start-up organisation and building its strategic framework

The European Personalised Medicine Diagnostics Association (EPEMED) has appointed Anne Bruinvels, an entrepreneur in personalised healthcare, as executive director and board member.

Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.

‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.

Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.

Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.

You may also like

Manufacturing

Pharmaceutical labelling in focus at Interpack 2026

Well prepared for new requirements. The upcoming reform of EU pharmaceutical legislation is expected to bring stricter requirements for traceability and labelling. The new 152E HC wrap-around labelling machine, developed specifically for contract packers, covers a wide product range with minimal change parts. Also on display: specialised labelling machines for automated product handling of small batches and high-speed labelling applications.
Cell & Gene Therapy

First CAR-T therapy for solid tumours set to launch in China

Claudin18.2-targeting CAR-T therapy satri-cel (CT041) is expected to become the first treatment of its kind for solid tumours, offering a new option for patients with advanced gastrointestinal cancers
Manufacturing

Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system

Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
Marketing

Ofichem consolidates six brands into single integrated CDMO and pharmaceutical supplier identity

Dutch family-owned pharmaceutical company Ofichem has unified its six business units — spanning API, drug substance, drug product and distribution — under a single trading name
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Subscribe now